Trials / Completed
CompletedNCT02125578
A Multiple Dose Safety Study of PEG-IFN in Healthy Volunteers
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Dose-Ranging, Parallel-Group Study of PEGylated Interferon Beta-1a (BIIB017) in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 69 (actual)
- Sponsor
- Biogen · Industry
- Sex
- All
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
The primary objectives are to identify the highest safe and well-tolerated dose and frequency of BIIB017 (PEGylated Interferon Beta-1a) subcutaneous (SC), within the range of 63 to 188 mcg, when given every other week or every 4 weeks to healthy volunteers (HV).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BIIB017 (PEGylated Interferon Beta-1a) | Each participant will receive BIIB017 every other week or every 4 weeks. |
| DRUG | Placebo | Each participant will receive placebo every other week or every 4 weeks. |
Timeline
- Start date
- 2008-03-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2014-04-29
- Last updated
- 2014-04-29
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02125578. Inclusion in this directory is not an endorsement.